State of the art in the clinical treatment of endotoxic shock.
Sepsis is a major health problem and remains an important cause of death worldwide. The failure to convert advances in our understanding of the biologic features of sepsis into effective new therapies questions the current approach to the development of sepsis drugs, and suggests a need for newer and better clinical trial design. Blood purification for sepsis is a promising therapeutic strategy to improve survival and reduce organ failure in patients with severe sepsis and septic shock.
Critical Care Center, Sabadell Hospital, CIBER Enfermedades Respiratorias, Corporació Sanitària Universitària Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Spain.
Antonio
A
Artigas
Pasquale
P
Piccinni
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006440:Hemofiltration / Q000379:methods*; D006801:Humans; D011112:Polymyxin B / Q000627:therapeutic use*; D012772:Shock, Septic / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*
D000900:Anti-Bacterial Agents; D011112:Polymyxin B